Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 11:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 15,138 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Randomized Controlled Study Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD0914

NCT01929629
View directory record Official record
Conditions
Gonococcal (GC) Infection
Interventions
Part A, Part B
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Oct 28, 2026, 11:22 PM EDT
Not listed Phase 2 Interventional

A Study to Evaluate Safety and Efficacy of PHX1149T in Subjects With Type 2 Diabetes Mellitus

NCT00482950
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
PHX1149T
Drug
Lead sponsor
Phenomix
Industry
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
22
States / cities
Chula Vista, California • Fullerton, California • Long Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2009 · Synced Oct 28, 2026, 11:22 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults

NCT07540910
View directory record Official record
Conditions
Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Interventions
EDP-978, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 28, 2026, 11:22 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Vimseltinib for Tenosynovial Giant Cell Tumor

NCT05059262
View directory record Official record
Conditions
Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Diffuse, Tenosynovial Giant Cell Tumor, Localized
Interventions
Vimseltinib, Placebo
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
11
States / cities
Duarte, California • Sacramento, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 28, 2026, 11:22 PM EDT
Completed Phase 2 Interventional Results available

MP1032 Treatment in Patients With Moderate to Severe COVID-19

NCT04932941
View directory record Official record
Conditions
COVID-19
Interventions
MP1032, Placebo
Drug
Lead sponsor
MetrioPharm AG
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Idaho Falls, Idaho • Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 28, 2026, 11:22 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

NCT05832151
View directory record Official record
Conditions
Diabetic Gastroparesis
Interventions
CIN-102 Dose 15mg or 10mg, Placebo
Drug
Lead sponsor
CinDome Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
100
States / cities
Dothan, Alabama • Foley, Alabama • Huntsville, Alabama + 82 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 28, 2026, 11:22 PM EDT
Completed Phase 2 Interventional

A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

NCT01225380
View directory record Official record
Conditions
Chronic Hepatitis C Infection
Interventions
GS-9190, GS-9256, Pegasys®, Copegus®, GS-9190 placebo, GS-9256 placebo
Drug · Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
36
States / cities
Phoenix, Arizona • Anaheim, California • La Jolla, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2014 · Synced Oct 28, 2026, 11:22 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2B Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversal of Ticagrelor in Subjects Aged 50-80 Years Old

NCT04122170
View directory record Official record
Conditions
Healthy
Interventions
Ticagrelor Oral Tablet - Pre-Treatment, Aspirin (ASA) Oral Tablet - Pre-Treatment, Bentracimab (PB2452) Infusion, Placebo (0.9% Sodium chloride) infusion
Drug
Lead sponsor
SFJ Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
207 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
13
States / cities
Rogers, Arkansas • Cypress, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 28, 2026, 11:22 PM EDT
Active, not recruiting Phase 2 Interventional

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT06967805
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
MTX-463, Placebo
Biological · Other
Lead sponsor
Mediar Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Newport Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 28, 2026, 11:22 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

NCT05147805
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Palmitil, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 28, 2026, 11:22 PM EDT
Completed Phase 1 Interventional Results available

AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis

NCT04897594
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
TERN-201, Placebo
Drug · Other
Lead sponsor
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
11
States / cities
Tucson, Arizona • Coronado, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 28, 2026, 11:22 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.

NCT03769194
View directory record Official record
Conditions
Lyme Borreliosis
Interventions
VLA15, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
572 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
6
States / cities
Milford, Connecticut • Stamford, Connecticut • Binghamton, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 28, 2026, 11:22 PM EDT
Completed Not applicable Interventional Results available

Calhoun Vision Light Adjustable Lens (LAL) in Subjects With Pre-Existing Corneal Astigmatism

NCT01496066
View directory record Official record
Conditions
Cataract
Interventions
LAL (Light Adjustable Lens) and Light Deliver Device (LDD), Monofocal control IOL
Device
Lead sponsor
Calhoun Vision, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
17
States / cities
Fayetteville, Arkansas • Los Angeles, California • Torrance, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2018 · Synced Oct 28, 2026, 11:22 PM EDT
Completed Phase 2 Interventional Results available

A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults

NCT02623322
View directory record Official record
Conditions
Influenza A
Interventions
MHAA4549A, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
38
States / cities
Athens, Alabama • Costa Mesa, California • Fountain Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 28, 2026, 11:22 PM EDT
Recruiting Phase 3 Interventional

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

NCT07355218
View directory record Official record
Conditions
Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus
Interventions
Enpatoran, Placebo, Standard of care (SoC)
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
14
States / cities
Upland, California • DeBary, Florida • Fort Lauderdale, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 28, 2026, 11:22 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation Of PF-00572778 And Alprazolam On Naloxone Challenge In Healthy Subjects

NCT00580190
View directory record Official record
Conditions
Healthy
Interventions
alprazolam, Placebo, PF-00572778
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 14, 2009 · Synced Oct 28, 2026, 11:22 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating JUVÉDERM® VOLUMA® XC Injectable Gel for Correction of Temple Hollowing in Adult Participants ≥ 22 Years Old

NCT04414397
View directory record Official record
Conditions
Temple Hollowing
Interventions
JUVÉDERM® VOLUMA® XC, No-treatment control
Device · Other
Lead sponsor
Allergan
Industry
Eligibility
22 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
14
States / cities
Los Angeles, California • Newport Beach, California • Boca Raton, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 28, 2026, 11:22 PM EDT
Not yet recruiting Not applicable Interventional

Fuzzle System for Appetite Control and Weight Management

NCT07527559
View directory record Official record
Conditions
Obesity & Overweight
Interventions
Fuzzle Intraoral Device, Lifestyle Management
Device · Behavioral
Lead sponsor
Fuzzle Operating Co.
Industry
Eligibility
18 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Bradenton, Florida
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 28, 2026, 11:22 PM EDT
Completed Phase 4 Interventional Results available

Study of Oasis Ultra in Diabetic Foot Ulcers

NCT01835379
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Oasis, Standard
Device · Other
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
16
States / cities
Little Rock, Arkansas • Carlsbad, California • Fair Oaks, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2015 · Synced Oct 28, 2026, 11:22 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001

NCT01224262
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine), LIQ001 (0.45mg), LIQ001 (1.8mg)
Biological
Lead sponsor
Liquidia Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated Mar 1, 2013 · Synced Oct 28, 2026, 11:22 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)

NCT02945046
View directory record Official record
Conditions
Episodic Cluster Headache
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
31
States / cities
Phoenix, Arizona • Canoga Park, California • Santa Monica, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 28, 2026, 11:22 PM EDT
Completed Not applicable Interventional

The Effects of Topical Calcium Glycerophosphate on Surgical Wound Healing and Residual Scarring

NCT01264588
View directory record Official record
Conditions
Wound Healing, Scarring
Interventions
Topical calcium glycerophosphate lotion
Other
Lead sponsor
AkPharma Inc.
Industry
Eligibility
45 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Egg Harbor, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 22, 2010 · Synced Oct 28, 2026, 11:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris

NCT06063473
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene Cream 0.005%, Placebo, AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories)
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
762 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 28, 2026, 11:22 PM EDT
Completed Phase 2 Interventional Results available

A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume

NCT00816023
View directory record Official record
Conditions
Bloodloss, Surgical Procedures, Operative
Interventions
ecallantide, placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 85 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
21
States / cities
Birmingham, Alabama • Montgomery, Alabama • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2015 · Synced Oct 28, 2026, 11:22 PM EDT